G C A T
T A C G
G C A T
genes
Article
Delineating the Spectrum of Genetic Variants Associated with
Bardet-Biedl Syndrome in Consanguineous Pakistani Pedigrees
Ali Raza Rao 1 , Aamir Nazir 2 , Samina Imtiaz 3 , Sohail Aziz Paracha 2 , Yar Muhammad Waryah 4 , Ikram Din Ujjan 5 ,
Ijaz Anwar 6 , Afia Iqbal 7 , Federico A. Santoni 8,9 , Inayat Shah 2 , Khitab Gul 3,10 , Hafiz Muhammad
Azhar Baig 6,11 , Ali Muhammad Waryah 1, * , Stylianos E. Antonarakis 8,12 and Muhammad Ansar 6,8,13, *
1
2
3
4
5
6
7
8
9
10
11
12
13
*
Citation: Rao, A.R.; Nazir, A.; Imtiaz,
S.; Paracha, S.A.; Waryah, Y.M.; Ujjan,
I.D.; Anwar, I.; Iqbal, A.; Santoni, F.A.;
Shah, I.; et al. Delineating the
Spectrum of Genetic Variants
Associated with Bardet-Biedl
Syndrome in Consanguineous
Pakistani Pedigrees. Genes 2023, 14,
404. https://doi.org/10.3390/
genes14020404
Academic Editor: Rui Chen
Received: 12 January 2023
Revised: 29 January 2023
Accepted: 30 January 2023
Published: 3 February 2023
Molecular Biology and Genetics Department, Medical Research Center, Liaquat University of Medical and
Health Sciences, Jamshoro 76090, Pakistan
Institute of Basic Medical Sciences, Khyber Medical University, Peshawar 25100, Pakistan
Department of Genetics, University of Karachi, Karachi 75270, Pakistan
Scientific and Ophthalmic Research Laboratory, Sindh Institute of Ophthalmology and Visual Sciences,
Hyderabad 71000, Pakistan
Department of Pathology, Liaquat University of Medical and Health Sciences, Jamshoro 76090, Pakistan
Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile Des
Aveugles, 1004 Lausanne, Switzerland
Department of Zoology, Lahore College for Women University, Lahore 54810, Pakistan
Department of Genetic Medicine and Development, University of Geneva, 1211 Geneva, Switzerland
Department of Endocrinology Diabetes and Metabolism, University Hospital of Lausanne,
1011 Lausanne, Switzerland
Department of BioSciences, Faculty of Life Science, Mohammad Ali Jinnah University, Karachi 75400, Pakistan
Department of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics,
The Islamia University of Bahawalpur, Bahawalpur 63080, Pakistan
iGE3 Institute of Genetics and Genomics of Geneva, 1211 Geneva, Switzerland
Advanced Molecular Genetics and Genomics Disease Research and Treatment Centre,
Dow University of Health Sciences, Karachi 74200, Pakistan
Correspondence: aliwaryah@lumhs.edu.pk (A.M.W.); muhammad.ansar@fa2.ch (M.A.)
Abstract: This study aimed to find the molecular basis of Bardet-Biedl syndrome (BBS) in Pakistani consanguineous families. A total of 12 affected families were enrolled. Clinical investigations were performed to access the BBS-associated phenotypes. Whole exome sequencing was
conducted on one affected individual from each family. The computational functional analysis
predicted the variants’ pathogenic effects and modeled the mutated proteins. Whole-exome sequencing revealed 9 pathogenic variants in six genes associated with BBS in 12 families. The
BBS6/MKS was the most common BBS causative gene identified in five families (5/12, 41.6%),
with one novel (c.1226G>A, p.Gly409Glu) and two reported variants. c.774G>A, Thr259LeuTer21
was the most frequent BBS6/MMKS allele in three families 3/5 (60%). Two variants, c.223C>T,
p.Arg75Ter and a novel, c. 252delA, p.Lys85STer39 were detected in the BBS9 gene. A novel 8bp
deletion c.387_394delAAATAAAA, p. Asn130GlyfsTer3 was found in BBS3 gene. Three known
variants were detected in the BBS1, BBS2, and BBS7 genes. Identification of novel likely pathogenic
variants in three genes reaffirms the allelic and genetic heterogeneity of BBS in Pakistani patients.
The clinical differences among patients carrying the same pathogenic variant may be due to other
factors influencing the phenotype, including variants in other modifier genes.
Keywords: retinitis pigmentosa; BBS; genetic variants; Pakistan
Copyright: © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
1. Introduction
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive genetic disorder, with
at least 26 genes reported to cause BBS in different ethnicities [1]. BBS shows variable
intra-familial and inter-familial phenotypes; the clinical presentations may include retinal
4.0/).
Genes 2023, 14, 404. https://doi.org/10.3390/genes14020404
https://www.mdpi.com/journal/genes
Genes 2023, 14, 404
2 of 13
degeneration and strabismus, postaxial polydactyly, obesity, hypogonadism, intellectual
disability, hepatic fibrosis, diabetic mellitus and speech deficits [2,3].
The BBS-associated genes encode numerous ciliary-associated proteins [4]. Primary
cilia are responsible for photoreceptor function in the retina and permit the transport of
molecules in photoreceptors. Cilia dysfunction causes retinal degeneration, renal diseases,
obesity, cerebral anomalies, and diabetes [5]. Interaction of multiple BBS-associated genes
forms a BBSome-complex, essential in cilia formation. For example, the BBS6, BBS10, and
BBS12 proteins form a chaperonin complex, which acts with BBS7, BBS2, and BBS9 to form
the core of the BBSome protein complex [6].
The prevalence of BBS is variable among different world populations. The highest
incidence, 1/3700, has been reported in the Faroe Islands [7], followed by 1/17,000 and
1/18,000 in Newfoundland and Kuwaiti populations [8,9]. BBS is rare in the European
population and its prevalence varies from 1/125,000 to 1/160,000 in English and Swiss
populations [10,11], whereas it is even lower at 1 in 18 million in the Asian population [12].
The prevalence of BBS is not well defined in the Pakistani population; only 20 affected
families belonging to different ethnic groups have been reported. Further comparative
studies are needed to explore the genetic pattern of BBS in the Pakistani population.
The Pakistani population is genetically heterogeneous and the fraction of consanguineous marriages is higher than in other countries. 60% of marriages in the country
are consanguineous [13], resulting in increased autosomal recessive disorders. This study
aimed to determine the molecular cause of BBS in consanguineous families and further
study the phenotypic heterogeneity.
2. Materials and Methods
2.1. Enrollment of Participants
The Bioethics Committee approved this study of the University Hospitals of Geneva,
Geneva, Switzerland (Protocol number: CER 11–036) and the Research Ethics committee of
Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan. Informed written
consent was obtained from all participants. Clinical examination confirmed the BBSassociated phenotypes, and family history was recorded. Twelve consanguineous families
with a minimum of two affected siblings with BBS belonged to different ethnic groups and
regions of Pakistan. The LUBS-1 to LUBS6, LUBS-9, and LUBS-10 families were enrolled
from different cities of Sindh province and belonged to mixed ethnic groups. The CB-3
and CB-44 families have enrolled from Khyber Patktoon Khuwa (KPK) region, and both
originate from the same ethnic group. Both the RP-04 and VI-44 families were enrolled
from Punjab province and belonged to the same ethnic group.
2.2. Blood Sampling and Clinical History
Pedigrees of all families were drawn, and family history was recorded. Detailed clinical information was taken, and BBS-related phenotypic characteristics, including postaxial
polydactyly, brachydactyly, obesity, nystagmus, strabismus, intellectual disability, and obesity, were noted in every affected and normal individual (Table 1, Supplementary Figure S1).
Then, 10 mL blood sample was collected. DNA was extracted by using a standard optimized protocol [14].
2.3. Whole Exome Sequencing Data Analysis
Whole exome sequencing (WES) was performed at the University Hospital Geneva,
Geneva, Switzerland using SureSelect Human All Exon kit v5 (Agilent Technologies, Santa
Clara, CA, USA) on an Illumina HiSeq4000 [15]. Exome data were analyzed through a
customized pipeline, and we successfully used the following strategy to identify novel ID/DD
genes in consanguineous families [15,16]. The pipeline includes the Burrows–Wheeler aligner
tool (BWA), SAMtools, PICARD (http://broadinstitute.github.io/picard/ (15 June 2020)) and
GATK [17]. The human assembly GRCh37/hg19 was used for reference alignment [18]. WES
was performed in one affected member per family to an overall mean-depth base coverage
Genes 2023, 14, 404
3 of 13
of at least 100-fold, and >90% of the targeted region covered at least 20-fold. Mapping
of sequenced reads and variant calling was performed as described previously [15,16,19].
First, variants in the genes reported to cause BBS and/or retinitis pigmentosa (RP) were
extracted from the WES variant files to look for genetic diagnosis. Extracted variants were
filtered with a minor allele frequency <1% in the GnomAD [20] and our local database. The
remaining variants were prioritized according to (i) their predicted deleteriousness scores
calculated by the SIFT [21], PolyPhen [22] and MutationTaster [23], (ii) GERP scores [24]
to look at the conservation, (iii) the severity of the genetic alteration (e.g., truncation
vs missense vs synonymous variant). Cases in which we found pathogenic or likely
pathogenic variants in known BBS/RP genes were further investigated by genotyping all
family members through Sanger sequencing for the segregation of variants with the disease
phenotypes in corresponding families [25].
The human assembly GRCh37/hg19 was used for reference alignment [18]. WES was
performed in individuals; IV-8 of LUBS01, IV-3 of LUBS02, IV-1 of LUBS03, IV-2 of LUBS09,
IV-2 of LUBS05, IV-1 of LUBS06, IV-1 of RP-04, IV-4 of VI-65, IV-4 of CB03 and IV-2 of CB04.
Additionally, both parents and all siblings of all families were genotyped for the found
variants by sanger sequencing.
Sex
Age (Years)
Retinitis
Pigmentosa
Polydactyly
Intellectual Disability
Hypogonadism
Renal Failure
Obesity
Nystagmus
Deafness
Bone Deformity
Table 1. Clinical findings of the families affected with Bardet biedl syndrome.
IV:4
M
12
Yes
Yes
No
Yes
No
Yes
No
No
No
IV:5
M
08
Yes
Yes
No
NA
No
Yes
No
No
No
F
6
Yes
Yes
No
NA
No
Yes
No
No
No
IV:03
F
15
Yes
No
No
NA
No
Yes
No
No
No
IV:04
F
11
Yes
No
No
NA
No
Yes
Yes
No
No
IV:01
M
12
Yes
Yes
No
NA
NA
Yes
Yes
No
No
IV:04
F
5
Yes
Yes
No
NA
NA
Yes
No
No
No
IV:03
M
21
Yes
Yes
No
No
No
Yes
No
No
No
IV:04
M
17
Yes
Yes
No
No
No
Yes
No
No
No
V:02
M
14
Yes
Yes
No
No
No
Yes
Yes
No
No
V:05
F
07
Yes
Yes
No
NA
No
Yes
Yes
No
No
Family
Identity
Gene
Variants
LUBS-01
BBS6/
MKKS
c.775delA,
p.Thr259LeuTer21
IV:8
LUBS-02
LUBS-03
LUBS-04
LUBS-05
BBS6/
MKKS
MKKS
BBS9
BBS1
c.775-delA,
p.Thr259LeuTer21
c.748G>A,
p.gly250Arg
c.223C>T,
p.Arg75Ter
c.1150
C>T,Glu384Ter
IV:01
M
06
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
IV:02
F
03
Yes
Yes
No
Yes
Yes
Yes
No
No
No
Genes 2023, 14, 404
4 of 13
Bone Deformity
Deafness
Nystagmus
Obesity
Renal Failure
c.471 +1G>A
Hypogonadism
BBS2
Intellectual Disability
LUBS-06
Polydactyly
Variants
Retinitis
Pigmentosa
Gene
Age (Years)
Family
Identity
Sex
Table 1. Cont.
No
IV:01
M
30
Yes
Yes
NA
Yes
No
Yes
Yes
No
No
IV:02
M
18
Yes
Yes
NA
Yes
No
Yes
Yes
No
No
LUBS-09
MKKS
c.775delA,
p.Thr259LeuTer21
IV:01
M
10
Yes
Yes
Yes
No
No
Yes
Yes
No
No
IV:02
F
14
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
F
17
Yes
Yes
Yes
NA
NA
Yes
Yes
No
No
M
16
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
M
18
Yes
Yes
yes
Yes
No
Yes
yes
No
No
M
30
Yes
Yes
No
NA
NA
Yes
Yes
No
No
F
34
Yes
Yes
No
NA
NA
Yes
Yes
No
No
IV:03
LUBS-10
BBS9
c.252delA,
p.Lys85SerTer39
IV:02
IV:03
CB-03
BBS7
c.580_582delGCA,
p.Ala194del
IV:01
IV:04
CB-44
BBS7
c.580_582delGCA,p.Ala194del
IV:01
M
11
Yes
Yes
No
NA
NA
Yes
Yes
No
No
IV:02
M
22
Yes
Yes
Yes
NA
NA
Yes
Yes
No
No
IV:03
M
21
Yes
Yes
Yes
NA
NA
Yes
Yes
No
No
M
19
Yes
No
No
No
No
No
No
No
No
IV:04
F
10
Yes
No
No
No
No
No
No
No
No
IV:06
M
12
Yes
Yes
No
No
No
Yes
No
No
No
IV:01
M
20
Yes
Yes
No
No
No
No
No
No
No
IV:02
M
25
Yes
No
No
No
No
No
No
No
No
VI-65
ARL6
c.387_394delAAATAAAA
IV:01
RP-04
MKKS
1226G>A,p.Gly409Glu
2.4. Sanger Sequencing Method
Sanger sequencing was performed at the Department of Molecular Biology and Genetics,
Liaquat University of Medical and Health Sciences, Jamshoro Sindh, Pakistan. Primer pairs
were designed to amplify variants using the Primer 3 web tool (Supplementary Table S1).
The sequencing reaction was carried out for affected families and 60 normal controls using
the previously described Big dye terminator Sanger sequencing kit [16]. The samples were
electrophoresed using Genetic analyzer 3130, and the chromatograms were analyzed using
chromas ver 3.
2.5. Computational Analysis for Protein Predictions
Bioinformatic analysis was performed for in silico predictions of pathogenic variants
and their effects on the encoded protein. For non-synonymous substitutions, Polyphen2 [26],
Sift, Mutation taster, and HOPE (Have your Protein Explained) protein prediction web
tool were used and Provean, and Editseq were used for Frameshift variants [22,23,27]. The
Phyre2 bioinformatics tool was used to model the protein [28].
Genes 2023, 14, 404
5 of 13
3. Results
Twelve unrelated consanguineous families with more than two affected siblings with
BBS were enrolled from Sindh, Punjab, and KPK provinces of Pakistan. The medical examination confirmed the clinical diagnosis of BBS with variable clinical presentations, showing
interfamilial and intra-familial phenotypic differences. The exome sequencing revealed 9
likely causative variants; four novels and five reported in six different genes; these variants
were segregated with the disease phenotype in all 12 families. Two variants were detected in
the BBS9 (NM_198428.3) gene, including one nonsense substitution (c.223C>T, p.Arg75Ter)
and a second novel single base deletion, resulting in a frameshift followed by premature termination (c.252delA, p.Lys85SerTer39). An 8bp novel deletion, c.387_394delAAATAAAA,
pAsn130GlyfsTer3 was found in BBS3 (NM_001278293.3) gene and one novel substitution
1226G>A, p.Gly409Glu was identified in BBS6/MKKS (NM_170784.3) gene. The variants
were homozygous in each family studied. No disease alleles were detected in 120 ethnically
matched normal controls.
Five variants were previously reported, including a frameshift deletion (c.774delA,
Thr259LeuTer21), a missense substitution (c.748G>A, Gly250Arg) in BBS6/MKKS
(NM_170784.3), one nonsense substitution (c.1150G>T, p, Glu384Ter) in BBS1, one splice site
variation (c.471G>A) in BBS2 (NM_031885.5), and a 3bp inframe deletion (c.580_582delGCA,
p.A194del) in BBS7 (Supplementary Figure S2). The in silico functional studies supported
the pathogenic role of all variants found segregating with the BBS phenotype in the study
(Supplementary Table S2).
The BBS6/MKKS was the most common causative BBS gene in the study (41.6%,
5/12 families) and the c.774delA:p. (Thr259LeuTer21) was the frequent BBS6/MKKS variant found in three families (60%, 3/5). All five families harboring BBS6/MKKS variants
were consanguineous. The three families (LUBS-01, LUBS-02, and LUBS-09) carrying
c.774delA:p.(Thr259LeuTer21) were unrelated and belonged to different ethnic groups
(Figure 1). The clinical presentation of patients is described in Table 1; briefly, the age of
the patients carrying c.774delA:p. (Thr259LeuTer21) ranged from 6 to 17 years, with a
mean age of 12. There were three female and five male patients. The retinitis pigmentosa
and obesity were consistent phenotypic features among all affected individuals, whereas
polydactyly showed interfamilial and intra-familial variability. It is noteworthy that intellectual disability was observed in all three patients of LUBS09. In contrast, five patients
of the other two families had normal intellectual development. Two patients of LUBS01
and LUBS09 had hypogonadism, each belonging to LUBS01 and LUBS09. The protein
prediction showed that adenine deletion causes the frameshift and only results in a premature polypeptide of 259 amino acids. Another BBS6/MKKSreported missense variant
c.748G>A, p. (Gly250Arg) segregated with BBS in family LUBS-03 (Figure 1). This family belonged to the Pakhtoon ethnic group of Mirpur Khas, Sindh, and consisted of two
affected members, a boy and a girl, aged 12 and five years, respectively. Both patients
had polydactyly at birth, whereas the retinitis pigmentosa and obesity manifested at three
years. The in silico analysis revealed that this substitution (p.Gly250Arg) replaces glycine,
which is neutral and small in size, whereas arginine is positively charged and big. This
replacement of the amino acids might affect the binding function of the apical domain of the
BBS6/MKKS protein.
Two patients of the RP-04 family were carrying a novel substitution, resulting in a
missense variant c.1226G>A, p.Gly409Glu (Figure 2C). Both patients had night blindness as
the primary symptom, and only one (IV:01) presented with polydactyly. In silico analysis
showed that the wild and mutant amino acid differs in size, charge, and hydrophobicity. The mutant residue is bigger than the wild-type residue; the wild-type residue is
more hydrophobic than the mutant residue. The wild-type glycine is the most flexible
of all residues. This flexibility might be necessary for the protein’s function. Mutation
of this glycine can abolish this function. Mutation of a 100% conserved residue is usually damaging to the protein. The Proven, Polyphen and mutation tester tools indicate
Genes 2023, 14, 404
6 of 13
the change as harmful and disease-causing. In addition, this variant is not found in the
genomeAD database.
Figure 1. Pedigrees affected with Bardet-Biedl Syndrome carrying known variations in BBS genes.
Genes 2023, 14, 404
7 of 13
Figure 2. Bardet-Biedl Syndrome affected Pedigrees with novel variations showing chromatogram
along with the wild type and mutant protein models.
The Ramachandran plot was used to predict the effect of amino acid substitution on
protein structure. It compares the stereo-chemistry and geometry of wild and mutant types
of protein structure by analyzing the angles of amino acids. The wild type and mutant
proteins revealed a non-comparable range. The wild-type protein carried 82% and 17%
residues in favored and allowed regions, while the mutant structure had 87% and 8%
residues in favored and allowed regions (Figure 3A). The metaDome health map shows
that the glycine at 409 position is located in the TCP-1/cpn60 chaperonin family domain
and is found in the neutral region (Figure 3B).
Figure 3. Protein modeling and bioinformatics analysis of identified variants. (A) Ramachandran plot
for wild-type and mutated residues of the BBS6/MKKS gene. (B) MetaDome health map showing
BBS6/MKKS residue. (C) MetaDome health map showing BBS9 residues. (D) MetaDome health map
showing BBS3 residue.
A novel 8bp deletion c.387_394delAAATAAAA, resulting in truncation of the protein
p.Asn130GlyfsTer3 in the BBS3 gene (NM_001278293.3), was segregated with BBS in the
Genes 2023, 14, 404
8 of 13
VI-65 family (Figure 2D). The clinical examination of three patients showed that retinitis
pigmentosa was the consistent phenotype in all the patients, whereas only one had polydactyly. The deletion of 8 nucleotides removes conserved amino acids and results in a
non-homologous sequence. (Figure 2D). The deletions may disturb the small GTP-binding
protein domain and GTP hydrolysis activity of the BBS3 gene. The metaDome analysis
revealed that Asn 130 amino acid is located in an intolerant region of ADP-ribosylation
(Figure 3D).
A previously reported BBS1 (NM_024649.5) variant, c.1150G>T: p.(Glu384Ter), was
found segregating with BBS in two affected individuals of family LUBS-05 (Figure 1). The
family belonged to the Pathan ethnic group and was enrolled from Dadu, Sindh, Pakistan.
Both affected individuals were diagnosed with retinitis pigmentosa, obesity, polydactyly,
and hypogonadism. The affected boy (IV-1) also manifested intellectual disability. The
c.1150G>T substitution introduces premature stop codon at the 384th residue of BBS1
protein, affecting the apical domain and impairing binding properties.
Two truncating mutations were detected in the BBS9 (NM_198428.3) gene, segregating
with BBS in two unrelated families (Figure 2A,B). LUBS04 consisted of four affected individuals who belonged to the Sindhi ethnic group (Figure 2A). All the affected individuals
had retinitis pigmentosa as the primary phenotype, polydactyly, and obesity. None of
the affected family LUBS04 had intellectual disability and hypogonadism. The exome
sequencing revealed nonsense codon in homozygosity, c.223C>T, p.Arg75Ter; the truncated
protein is only 75 amino acids long and lacks the functionally important conserved Pfam
domain. This allele was previously reported in Danish and Saudi cohorts [29,30]; however,
no details of this variant’s clinical and in silico functional data are available in the literature.
Our bioinformatics analysis supported this change as disease-causing. The metaDome
analysis revealed that the truncated Arg75 amino acid is located in the neutral region of the
N-terminal domain of the PTHB1 protein (Figure 3C).
The second novel homozygous variant c.252delA, p.Lys85SerTer39 in the BBS9 resulted in a frameshift and truncation of the protein at the 39th amino acid, segregating
with BBS in family LUBS10 (Figure 2B). The affected individuals had consistent typical
symptoms, including RP, polydactyly, and obesity. In addition, both affected were intellectually disabled. This variant affects the conserved Pfam domain of the BBS9 protein. The
bioinformatics analysis indicated this variation as disease-causing. The metaDome analysis
revealed that truncated Lysine at the 85th position is located in the slightly intolerant region
of the N-terminal domain of the PTHB1 protein (Figure 3C).
One known splicing variant, IVS3 -1G>A, was found in the BBS2 gene, which segregated with the BBS phenotypes in two affected individuals of family LUBS06. Both
affected had RP, obesity, and intellectual disabilities, whereas polydactyly was absent in
both patients (Table 1). The family belonged to the Punjabi ethnic group and was enrolled
from Sindh province. The splice variant is predicted to cause the failure of removal of
intron-3, resulting in abnormal protein.
A 3bp deletion (c.580_582delGCA:p(Ala194del)) in BBS7 (NM_176824.3) gene segregated with the BBS phenotype in two unrelated families, CB03 and CB44. Both families
were enrolled from the KPK province of Pakistan and belonged to the same ethnic group,
Pashtun. The clinical findings showed that all five affected of the two families had RP,
polydactyly, obesity, and nystagmus. In contrast, intellectual disability was found only in
two affected individuals of family CB-44. Bioinformatics analysis showed that the deletion
of the conserved Ala194 deteriorated the normal protein structure and function.
4. Discussion
In this study, we expand the repertoire of BBS phenotypes caused by the reported
and novel variants in different BBS genes. We report 31 one affected individuals from
12 BBS families ascertained from different regions of Pakistan, who possess different
pathogenic and likely pathogenic homozygous variants in BBS genes. The study affirmed
the BBS6/MKKS alleles as the most common BBS-causing variants in Pakistani patients.
Genes 2023, 14, 404
9 of 13
(41.6% 5/12 families). The c.774delA was the frequent variant in the mutated 60% (3/5)
BBS6/MKKSfamilies. The allele frequency of the frequent BBS6/MKKS allele, c.774delA in
Pakistani patients was 24% (14/58) (Table 2). Our study showed a 41.6% (10/24 alleles) contribution of BBS6/MKKS alleles in the included families (Table 2). The global contribution is
insignificant; only one family carrying the BBS6/MKKS mutation was detected in 55 families
comprising European-derived American, Tunisian, Arabic, and Pakistani patients [31]. To
date, 60 pathogenic variations have been reported in the BBS6/MKKS gene, most of which
are missense and nonsense mutations [32]. Notably, the frequent mutation c.774delA was
first detected in a Pakistani family. In contrast, the second missense variant found in the
study, p.Gly250Arg was initially detected in a Spanish family [33]. This study identifies a
novel BBS6/MKKS variant, p.Gly409Glu, indicating the allelic heterogeneity. A haplotype
of intragenic variants across the c.774delA was assessed in families LUBS01, LUBS02 and
LUBS09. A typical region of 3’033’925 bp was shared between family LUBS01 and LUBS02;
LUBS09 shared a 2’636’377 bp region with LUBS01 and LUBS02, indicating a founder
effect (Supplementary Table S3). Overall assessment of BBS6/MKKS-associated disease in
Pakistani patients ranks it as a frequently mutated gene, with 27% (16/58) prevalence in
the Pakistani patients studied. (Table 2).
Table 2. BBS associated variants detected in Pakistani patients.
Gene
Variants
No. of Families
No. of Alleles
Frequency
(gnomAD Database)
References
BBS1
c.1150G>T,p.Glu Ter384
1
2
0
[34]
c.47 +1G>T
1
2
0.00000399
c.442 G>A,p.Asp148Asn
1
2
0.00029
[35]
[35]
BBS2
c.471 +1G>A
1
2
0
[36]
BBS3/
ARL6
c.534A>G.p.Gln178Gln
1
2
0.00000796
[37]
c.387_394delAAATAAAA
1
2
0
In this study
BBS5
c.734_744del,p.Glu245Gly Ter18
2
4
0
[37]
BBS6/MKKS
c.775delA,
p.Thr259LeuTer21
4
8
0.0000438
[38]
In this study
c.1226G>A,pGly409Glu
1
2
0
c.287 C>T,p.Ala96Val
1
2
0
c.748 G>A,p.gly250Arg
1
2
0.0000159
c.822 C>G,p.Ser40 *
1
2
0
[38]
BBS7
c.580_582delGCA
3
6
0
[38]
c.1592_1592delTCCAG
1
2
0
BBS8
c.1347G>C,p.Gln449His
1
2
0
BBS9
c.223C>T, p.Arg Ter75
1
2
0.0000199
c.252delA,
p.Lys85S Ter39
1
2
0
c.299delC (p.Ser100Leu Ter24)
3
06
0
[40]
[39]
[38]
In this study
c.1789 C>T,p.Gln Ter597
1
2
0
[37]
BBS10
c.271_272insT
1
2
0.000579
[38]
BBS12
c.2014G>A,p.Ala672Thr
1
2
0.001102
[37]
29
58
Total
BBS9 variants are the second most frequent cause of BBS in Pakistan patients, with
20.6% (12/58) allelic contribution (Table 2). Previously, a single BBS9 deletion, c.299delC,
was found in three Pakistani families of the same ethnic group [33,39]. This study expands
the BBS9 mutation spectrum and adds two truncating variants c.223C>T, p.Arg75Ter and
a novel c.252delA:p.Lys85SerTer39, associated with BBS in two unrelated pedigrees. The
Genes 2023, 14, 404
10 of 13
BBS9 gene plays a central role in binding BBSome constituting proteins (BBS1 to BBS10),
and the loss of function mutations may affect the integrity of the BBSome complex [6]. The
affected of both families carrying novel variations presented three consistent phenotypic
features, including RP, polydactyly, and obesity. In addition, LUBS10 patients had intellectual disability and hypogonadism (Table 1). The previously reported Pakistani families
carrying a loss of function variant showed the same significant clinical symptoms, except
for intellectual disability and hypogonadism. However, the two tested patients were adults
aged 20 and 18 [38]. This phenotypic variation among the families reported in this study
and previously reported pedigree may be due to different ethnic lineages.
Previously, three different mutations in the BBS3 gene have been identified in three
Pakistani families affected with BBS; one of the homozygous variants is a deletion of
54 Kb [31,40,41]. Notably, four other large deletions in BBS3 were found in BBS families from Saudi Arabia, France and USA [37,38]. In this study, a novel 8 bp deletion
(c.387_394delAAATAAAA) was inherited recessively in three patients of BBS. Initial clinical
assessment of the proband indicated a nonsyndromic RP; however, the examination of all
other affected showed unilateral polydactyly in one patient. Previously, nonsyndromic
RP has been reported in Saudi Arabian patients carrying homozygous missense variants
(p.Ala89Val) in the BBS3 gene. In contrast, patients with a deletion, c.732+1952_899-3806del4139, showed polydactyl, obesity, and dysmorphism [42]. The variable phenotype may
be due to different types and locations of BBS3 variants.
BBS1 mutations are uncommon in Pakistani patients; previously, only one family
with a splice site mutation was reported. We identified another BBS family carrying biallelic substitution p.Glu384Ter, resulting in the termination of the protein. Previously,
c.1150G>T was detected as a compound heterozygous with a missense allele, Met390Arg,
in French patients [42]. This study described the first report of homozygousp.Glu384Ter
from Pakistan. The BBS1 mutations are more frequent in Caucasian patients; the founder
variant p.(Met390Arg) has been homozygous and compound heterozygous in more than
15 families [34,43]. In addition, BBS1 variants cause mild ocular and renal abnormalities [6,34].
Our patients, homozygous for the BBS1 variant, showed early onset of RP at 3 and 6 years
and renal anomalies. These clinical differences may be due to the nature of the variant;
the Caucasian patients harbored missense variants, whereas our patients carried bi-allelic
truncation mutations. In addition, epigenetic or environmental factors may also aggravate
the phenotype.
Identification of BBS mutation in the BBS2 gene elaborates clinical and genetic heterogeneity in BBS patients of Pakistan. Previously no disease allele of BBS2 has been reported
in Pakistani patients. We detected a splice site variant, IVS3 -1G>A, in two patients of
the LUBS06 family, which was initially reported in an isolated case affected with nonsyndromic retinitis pigments [44]. The affected individuals of family LUBS06 presented with
typical characteristics and features of BBS, including polydactyly and obesity (Table 1). Our
findings show that the IVS3 -1G>A segregates with BBS phenotype in a consanguineous
pedigree, an additional variant phenotype.
BBS7 mutation p.(Ala194del) segregated BBS into two families of the Pathan ethnic
group. The clinical assessment showed interfamilial differences among patients despite the
same variant and ethnicity. Two patients of the CB44 family had an intellectual disability,
whereas no such phenotype was present in family CB03. This deletion was first reported in
a Pakistani family of the same ethnicity, and the patients had RP, obesity, and intellectual
disability [38]. Our study indicates that p.Ala194del is the recurrent BBS mutation of
Pathan ethnicity and KPK province. The haplotype analysis showed a shared region of
5,063,463 bp long between the two families and indicated a common origin of the variant.
5. Conclusions
BBS is a rare disorder, and this is the largest cohort of consanguine BBS families,
characterized by the molecular basis of the disease. The BBS6/MKKS and BBS9 are the
frequent genes associated with BBS in the Pakistani population, and identifying novel
Genes 2023, 14, 404
11 of 13
variants reaffirms the allelic heterogeneity. In addition, the differences in clinical manifestation and severity of the disease in patients carrying the same mutated allele indicate the
contribution of other factors, including additional genomic variations. This study provides
carrier screening and genetic counseling opportunities for affected families and helps in
the prognosis and management of patients with BBS.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/genes14020404/s1, Figure S1: Phenotypic features of families
affected with BBS; Figure S2: Chromatograms of common known variants; Table S1: Sequencing
primers used for selected exons of BBS genes; Table S2: Predictions of bioinformatics tools for
variants segregating in families affected with Bardet Biedal Syndrome (BBS); Table S3: Haplotype of
interagenic variants across the BBS6/MKKS and BBS7 common variants.
Author Contributions: M.A., S.E.A., A.M.W. and I.D.U. Designed and conceived the study, provided
resources and supervised the experiments. A.R.R., A.N., Y.M.W., I.A., S.I., S.A.P., A.I., I.S., H.M.A.B.,
F.A.S. and K.G. Ascertained the subjects, performed clinical phenotyping and data analysis. A.R.R.,
Y.M.W., A.M.W. and M.A., wrote the manuscript. All authors have read and agreed to the published
version of the manuscript.
Funding: This study was funded by Swiss National Science Foundation: 320030_212959 grant to
M.A. and Higher Education Commission Pakistan grant: NRPU 2835 to A.M.W.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Institutional Review Board and Ethics committees
of University Hospitals of Geneva, Geneva, Switzerland (Protocol number: CER 11–036) and the
Research Ethics committee of Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan.
This study was partially supported by the Swiss National Science Foundation grant (320030_212959).
A part of the study was supported by Higher Education Commission of Pakistan NRPU#2835.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: Date may be provided on the request.
Acknowledgments: We would like to thank the families and all participating affected and normal
individuals who contributed to this study and the medical consultants involved in their care and
clinical diagnosis.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Forsyth, R.; Gunay-Aygun, M. Bardet-Biedl syndrome overview. In GeneReviews; National Institutes of Health: Bethesda, MD,
USA, 2020.
Beales, P.L.; Elcioglu, N.; Woolf, A.S.; Parker, D.; Flinter, F. New criteria for improved diagnosis of Bardet-Biedl syndrome: Results
of a population survey. J. Med. Genet. 1999, 36, 437–446. [CrossRef]
M’Hamdi, O.; Ouertani, I.; Chaabouni-Bouhamed, H. Update on the genetics of bardet-biedl syndrome. Mol. Syndromol. 2014, 5,
51–56. [CrossRef]
Forsythe, E.; Beales, P.L. Bardet–Biedl syndrome. Eur. J. Hum. Genet. 2013, 21, 8–13. [CrossRef]
Berbari, N.F.; Lewis, J.S.; Bishop, G.A.; Askwith, C.C.; Mykytyn, K. Bardet-Biedl syndrome proteins are required for the
localization of G protein-coupled receptors to primary cilia. Proc. Natl. Acad. Sci. USA 2008, 105, 4242–4246. [CrossRef]
Niederlova, V.; Modrak, M.; Tsyklauri, O.; Huranova, M.; Stepanek, O. Meta-analysis of genotype-phenotype associations in
Bardet-Biedl syndrome uncovers differences among causative genes. Hum. Mutat. 2019, 40, 2068–2087. [CrossRef]
Hjortshøj, T.D.; Grønskov, K.; Brøndum-Nielsen, K.; Rosenberg, T. A novel founder BBS1 mutation explains a unique high
prevalence of Bardet–Biedl syndrome in the Faroe Islands. Br. J. Ophthalmol. 2009, 93, 409–413. [CrossRef]
Moore, S.J.; Green, J.S.; Fan, Y.; Bhogal, A.K.; Dicks, E.; Fernandez, B.A.; Stefanelli, M.; Murphy, C.; Cramer, B.C.; Dean, J.C.S.;
et al. Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: A 22-year prospective, population-based,
cohort study. Am. J. Med. Genet. A 2005, 132A, 352–360. [CrossRef]
Teebi, A.S. Autosomal recessive disorders among Arabs: An overview from Kuwait. J. Med. Genet. 1994, 31, 224–233. [CrossRef]
Beales, P.L.; Warner, A.M.; Hitman, G.A.; Thakker, R.; Flinter, F.A. Bardet-Biedl syndrome: A molecular and phenotypic study of
18 families. J. Med. Genet. 1997, 34, 92–98. [CrossRef]
Klein, D.; Ammann, F. The syndrome of Laurence-Moon-Bardet-Biedl and allied diseases in Switzerland. Clinical, genetic and
epidemiological studies. J. Neurol. Sci. 1969, 9, 479–513. [CrossRef]
Genes 2023, 14, 404
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
12 of 13
Cai, M.; Lin, M.; Lin, N.; Xu, L.; Huang, H. Novel homozygous nonsense mutation associated with Bardet-Biedl syndrome in
fetuses with congenital renal malformation. Medicine 2022, 101, e30003. [CrossRef]
Iqbal, S.; Zakar, R.; Fischer, F.; Zakar, M.Z. Consanguineous marriages and their association with women’s reproductive health
and fertility behavior in Pakistan: Secondary data analysis from Demographic and Health Surveys, 1990–2018. BMC Women’s
Health 2022, 22, 118. [CrossRef]
Hamamy, H. Consanguineous marriages: Preconception consultation in primary health care settings. J. Community Genet. 2012, 3,
185–192. [CrossRef]
Ansar, M.; Chung, H.; Waryah, Y.M.; Makrythanasis, P.; Falconnet, E.; Rao, A.R.; Guipponi, M.; Narsani, A.K.; Fingerhut, R.;
Santoni, F.A.; et al. Visual impairment and progressive phthisis bulbi caused by recessive pathogenic variant in MARK3. Hum.
Mol. Genet. 2018, 27, 2703–2711. [CrossRef]
Ansar, M.; Riazuddin, S.; Sarwar, M.T.; Makrythanasis, P.; Paracha, S.A.; Iqbal, Z.; Khan, J.; Assir, M.Z.; Hussain, M.; Razzaq, A.;
et al. Biallelic variants in LINGO1 are associated with autosomal recessive intellectual disability, microcephaly, speech and motor
delay. Genet. Med. 2018, 20, 778–784. [CrossRef]
Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 2009, 25, 1754–1760.
[CrossRef]
DePristo, M.A.; Banks, E.; Poplin, R.; Garimella, K.V.; Maguire, J.R.; Hartl, C.; Philippakis, A.A.; del Angel, G.; Rivas, M.A.;
Hanna, M.; et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet.
2011, 43, 491–498. [CrossRef]
Mattioli, F.; Darvish, H.; Paracha, S.A.; Tafakhori, A.; Firouzabadi, S.G.; Chapi, M.; Baig, H.M.A.; Reymond, A.; Antonarakis, S.E.;
Ansar, M. Biallelic truncation variants in ATP9A are associated with a novel autosomal recessive neurodevelopmental disorder.
NPJ Genom. Med. 2021, 6, 94. [CrossRef]
Gudmundsson, S.; Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alföldi, J.; Wang, Q.; Collins, R.L.; Laricchia, K.M.;
Ganna, A.; et al. Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2021, 597,
E3–E4. [CrossRef]
Kumar, P.; Henikoff, S.; Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT
algorithm. Nat. Protoc. 2009, 4, 1073–1081. [CrossRef] [PubMed]
Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.; Kondrashov, A.S.; Sunyaev, S.R. A method and
server for predicting damaging missense mutations. Nat. Methods 2010, 7, 248–249. [CrossRef] [PubMed]
Schwarz, J.M.; Cooper, D.N.; Schuelke, M.; Seelow, D. MutationTaster2: Mutation prediction for the deep-sequencing age. Nat.
Methods 2014, 11, 361–362. [CrossRef] [PubMed]
Cooper, G.M.; Stone, E.A.; Asimenos, G.; Green, E.D.; Batzoglou, S.; Sidow, A. Distribution and intensity of constraint in
mammalian genomic sequence. Genome Res. 2005, 15, 901–913. [CrossRef]
Shaikh, H.; Waryah, A.M.; Narsani, A.K.; Iqbal, M.; Shahzad, M.; Waryah, Y.M.; Shaikh, A.; Mahmood, A. Genetic testing of
non-familial deaf patients for CIB2 and GJB2 mutations: Phenotype and genetic counselling. Biochem. Genet. 2017, 55, 410–420.
[CrossRef] [PubMed]
Waryah, Y.M.; Iqbal, M.; Sheikh, S.A.; Baig, M.A.; Narsani, A.K.; Atif, M.; Bhinder, M.A.; Rahman, A.U.; Memon, A.I.; Pirzado,
M.S.; et al. Two novel variants in CYP1B1 gene: A major contributor of autosomal recessive primary congenital glaucoma with
allelic heterogeneity in Pakistani patients. Int. J. Ophthalmol. 2019, 12, 8. [PubMed]
Venselaar, H.; Te Beek, T.A.; Kuipers, R.K.; Hekkelman, M.L.; Vriend, G. Protein structure analysis of mutations causing inheritable
diseases. An e-Science approach with life scientist friendly interfaces. BMC Bioinform. 2010, 11, 548. [CrossRef]
Choi, Y.; Sims, G.E.; Murphy, S.; Miller, J.R.; Chan, A.P. Predicting the functional effect of amino acid substitutions and indels.
PLoS ONE 2012. [CrossRef]
Shaheen, R.; Szymanska, K.; Basu, B.; Patel, N.; Ewida, N.; Faqeih, E.; Al Hashem, A.; Derar, N.; Alsharif, H.; Aldahmesh, M.A.;
et al. Characterizing the morbid genome of ciliopathies. Genome Biol. 2016, 17, 242. [CrossRef]
Jespersgaard, C.; Fang, M.; Bertelsen, M.; Dang, X.; Jensen, H.; Chen, Y.; Bech, N.; Dai, L.; Rosenberg, T.; Zhang, J.; et al. Molecular
genetic analysis using targeted NGS analysis of 677 individuals with retinal dystrophy. Sci. Rep. 2019, 9, 1219. [CrossRef]
Kelley, L.A.; Mezulis, S.; Yates, C.M.; Wass, M.N.; Sternberg, M.J. The Phyre2 web portal for protein modeling, prediction and
analysis. Nat. Protoc. 2015, 10, 845–858. [CrossRef]
Chen, J.; Smaoui, N.; Hammer, M.B.H.; Jiao, X.; Riazuddin, S.A.; Harper, S.; Katsanis, N.; Riazuddin, S.; Chaabouni, H.; Berson,
E.L.; et al. Molecular analysis of Bardet-Biedl syndrome families: Report of 21 novel mutations in 10 genes. Investig. Ophthalmol.
Vis. Sci. 2011, 52, 5317–5324. [CrossRef] [PubMed]
Stenson, P.D.; Ball, E.V.; Mort, M.; Phillips, A.D.; Shaw, K.; Cooper, D.N. The Human Gene Mutation Database (HGMD) and
its exploitation in the fields of personalized genomics and molecular evolution. Curr. Protoc. Bioinform. 2012, 39, 1.13.1–1.13.20.
[CrossRef]
Ece Solmaz, A.; Onay, H.; Atik, T.; Aykut, A.; Gunes, M.C.; Yuregir, O.O.; Bas, V.N.; Hazan, F.; Kirbiyik, O.; Ozkinay, F. Targeted
multi-gene panel testing for the diagnosis of Bardet Biedl syndrome: Identification of nine novel mutations across BBS1, BBS2,
BBS4, BBS7, BBS9, BBS10 genes. Eur. J. Med. Genet. 2015, 58, 689–694. [CrossRef] [PubMed]
Genes 2023, 14, 404
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
13 of 13
Ajmal, M.; Khan, M.I.; Neveling, K.; Tayyab, A.; Jaffar, S.; Sadeque, A.; Ayub, H.; Abbasi, N.M.; Riaz, M.; Micheal, S.; et al. Exome
sequencing identifies a novel and a recurrent BBS1 mutation in Pakistani families with Bardet-Biedl syndrome. Mol. Vis. 2013, 19,
644–653. [PubMed]
Wang, F.; Wang, H.; Tuan, H.F.; Nguyen, D.H.; Sun, V.; Keser, V.; Bowne, S.J.; Sullivan, L.S.; Luo, H.; Zhao, L.; et al. Next generation
sequencing-based molecular diagnosis of retinitis pigmentosa: Identification of a novel genotype-phenotype correlation and
clinical refinements. Hum. Genet. 2014, 133, 331–345. [CrossRef]
Maria, M.; Lamers, I.J.; Schmidts, M.; Ajmal, M.; Jaffar, S.; Ullah, E.; Mustafa, B.; Ahmad, S.; Nazmutdinova, K.; Hoskins, B.;
et al. Genetic and clinical characterization of Pakistani families with Bardet-Biedl syndrome extends the genetic and phenotypic
spectrum. Sci. Rep. 2016, 6, 34764. [CrossRef]
Ullah, A.; Umair, M.; Yousaf, M.; Khan, S.A.; Shah, K.; Ahmad, F.; Azeem, Z.; Ali, G.; Alhaddad, B.; Rafique, A.; et al. Sequence
variants in four genes underlying Bardet-Biedl syndrome in consanguineous families. Mol. Vis. 2017, 23, 482–494.
Pereiro, I.; Valverde, D.; Piñeiro-Gallego, T.; Baiget, M.; Borrego, S.; Ayuso, C.; Searby, C.; Nishimura, D. New mutations in BBS
genes in small consanguineous families with Bardet-Biedl syndrome: Detection of candidate regions by homozygosity mapping.
Mol. Vis. 2010, 16, 137.
Muzammal, M.; Zubair, M.; Bierbaumer, S.; Blatterer, J.; Graf, R.; Gul, A.; Abbas, S.; Badar, M.; Abbasi, A.A.; Khan, M.A.; et al.
Exome sequence analysis in consanguineous Pakistani families inheriting Bardet-Biedle syndrome determined founder effect of
mutation c. 299delC (p. Ser100Leufs* 24) in BBS9 gene. Mol. Genet. Genom. Med. 2019, 7, e834.
Khan, S.; Ullah, I.; Touseef, M.; Basit, S.; Khan, M.N.; Ahmad, W. Novel homozygous mutations in the genes ARL6 and BBS10
underlying Bardet–Biedl syndrome. Gene 2013, 515, 84–88. [CrossRef]
Safieh, L.A.; Aldahmesh, M.A.; Shamseldin, H.; Hashem, M.; Shaheen, R.; Alkuraya, H.; Al Hazzaa, S.A.F.; Al-Rajhi, A.;
Alkuraya, F.S. Clinical and molecular characterisation of Bardet–Biedl syndrome in consanguineous populations: The power of
homozygosity mapping. J. Med. Genet. 2010, 47, 236–241. [CrossRef] [PubMed]
Hichri, H.; Stoetzel, C.; Laurier, V.; Caron, S.; Sigaudy, S.; Sarda, P.; Hamel, C.; Martin-Coignard, D.; Gilles, M.; Leheup, B.; et al.
Testing for triallelism: Analysis of six BBS genes in a Bardet–Biedl syndrome family cohort. Eur. J. Hum. Genet. 2005, 13, 607–616.
[CrossRef] [PubMed]
Daniels, A.B.; Sandberg, M.A.; Chen, J.; Weigel-DiFranco, C.; Hejtmancik, J.F.; Berson, E.L. Genotype-phenotype correlations in
Bardet-Biedl syndrome. Arch. Ophthalmol. 2012, 130, 901–907. [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.